HomeMarketSyndax Pharma...

Syndax Pharmaceuticals Inc. (SNDX) Stock is looking to regain its victory

Stifel raised the price target for the Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) stock to “a Buy”. The rating was released on January 31, 2023, according to finviz. The research report from B. Riley Securities has resumed the stock to Buy, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed in a research note on April 11, 2022, to Buy and set the price objective to $31. In their research brief published February 15, 2022, Goldman analysts initiated the Syndax Pharmaceuticals Inc. stock to Buy with a price target of $37.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) raised 0.90% to close Thursday’s market session at $22.50, higher as compared to yesterday’s close. The stock price fluctuated between $21.89 and $22.60 throughout the trading session with the volume trading being 1118319 shares, which represented a significant variation when compared to the three months average volume of 755.95K shares. The firm’s stock price fluctuated -3.06% within the last five trades and -14.29% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -5.74% in the last 6 months and -9.35% was subtracted to its value over the previous 3 months. SNDX stock is trading at a margin of -7.40%, -12.12% and -1.77% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


As of the close of trading, SNDX deals in the Healthcare domain. The stock is trading -24.65 percent below its 52-week high and 69.56 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 23.9. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Syndax Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $1.61 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 3.04, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.30 percent of Syndax Pharmaceuticals Inc. shares are owned by insiders, and 90.20 percent are held by financial institutions. Morrison Briggs, the President, Head of R&D at Syndax Pharmaceuticals Inc. (SNDX) has sold 52,854 shares of firm on Mar 13 at a price of $22.53 against the total amount of $1.19 million. In another inside trade, Ordentlich Peter, Chief Scientific Officer of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) sold 25,000 shares of the firm on Feb 15 for a total worth of $0.65 million at a price of $25.84. An inside trade which took place on Feb 06, President, Head of R&D of Syndax Pharmaceuticals Inc. Morrison Briggs sold 52,854 shares of firm against total price of $1.42 million at the cost of $26.83 per share.



Please enter your comment!
Please enter your name here

Recent Post